Athira Pharma Stock Buy Hold or Sell Recommendation
| ATHA Stock | USD 0.53 0.01 1.92% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Athira Pharma is 'Strong Sell'. Macroaxis provides Athira Pharma buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ATHA positions.
Check out Athira Pharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Athira Stock refer to our How to Trade Athira Stock guide. In addition, we conduct extensive research on individual companies such as Athira and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Athira Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
Athira |
Execute Athira Pharma Buy or Sell Advice
The Athira recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Athira Pharma. Macroaxis does not own or have any residual interests in Athira Pharma or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Athira Pharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Hold | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Athira Pharma Trading Alerts and Improvement Suggestions
| Athira Pharma generated a negative expected return over the last 90 days | |
| Athira Pharma has high historical volatility and very poor performance | |
| Athira Pharma has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (117.67 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Athira Pharma currently holds about 252.4 M in cash with (100.75 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.67, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 62.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Can Athira Pharma Afford To Invest In Growth - Yahoo Finance |
Athira Pharma Returns Distribution Density
The distribution of Athira Pharma's historical returns is an attempt to chart the uncertainty of Athira Pharma's future price movements. The chart of the probability distribution of Athira Pharma daily returns describes the distribution of returns around its average expected value. We use Athira Pharma price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Athira Pharma returns is essential to provide solid investment advice for Athira Pharma.
| Mean Return | 0.43 | Value At Risk | -8.47 | Potential Upside | 7.27 | Standard Deviation | 7.57 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Athira Pharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Athira Stock Institutional Investors
| Shares | Bristlecone Advisors Llc | 2024-09-30 | 337.5 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 321.4 K | Geode Capital Management, Llc | 2024-09-30 | 320.8 K | Two Sigma Investments Llc | 2024-09-30 | 258.5 K | Laird Norton Tyee Trust Co | 2024-09-30 | 147.3 K | State Street Corp | 2024-09-30 | 107.8 K | Bridgeway Capital Management, Llc | 2024-09-30 | 88.9 K | Advisor Group Holdings, Inc. | 2024-09-30 | 82.3 K | Qube Research & Technologies | 2024-09-30 | 63 K | Perceptive Advisors Llc | 2024-09-30 | 5.4 M | Vanguard Group Inc | 2024-09-30 | 1.6 M |
Athira Pharma Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Investments | (210.1M) | (2.5M) | 58.8M | 113.3M | 130.3M | 136.9M | |
| Change In Cash | 58.6M | 49.9M | (14.2M) | (5.2M) | (4.7M) | (4.4M) | |
| Free Cash Flow | (26.4M) | (44.7M) | (73.6M) | (101.1M) | (91.0M) | (86.4M) | |
| Depreciation | 251K | 479K | 845K | 969K | 1.1M | 1.2M | |
| Other Non Cash Items | 1.7M | 493K | (219K) | (1.2M) | (1.1M) | (1.0M) | |
| Net Income | (20.0M) | (54.9M) | (95.6M) | (117.7M) | (105.9M) | (100.6M) | |
| End Period Cash Flow | 60.6M | 110.5M | 96.4M | 91.2M | 104.9M | 66.8M | |
| Change To Netincome | 510K | 2.0M | 4.6M | 10.6M | 12.2M | 12.8M |
Athira Pharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Athira Pharma or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Athira Pharma's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Athira stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.35 | |
β | Beta against Dow Jones | 0.81 | |
σ | Overall volatility | 5.69 | |
Ir | Information ratio | 0.04 |
Athira Pharma Volatility Alert
Athira Pharma is displaying above-average volatility over the selected time horizon. Athira Pharma is a potential penny stock. Although Athira Pharma may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Athira Pharma. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Athira instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Athira Pharma Fundamentals Vs Peers
Comparing Athira Pharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Athira Pharma's direct or indirect competition across all of the common fundamentals between Athira Pharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Athira Pharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Athira Pharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Athira Pharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Athira Pharma to competition |
| Fundamentals | Athira Pharma | Peer Average |
| Return On Equity | -0.85 | -0.31 |
| Return On Asset | -0.48 | -0.14 |
| Current Valuation | (46.89 M) | 16.62 B |
| Shares Outstanding | 38.67 M | 571.82 M |
| Shares Owned By Insiders | 1.95 % | 10.09 % |
| Shares Owned By Institutions | 62.13 % | 39.21 % |
| Number Of Shares Shorted | 1.37 M | 4.71 M |
| Price To Book | 0.36 X | 9.51 X |
| EBITDA | (116.7 M) | 3.9 B |
| Net Income | (117.67 M) | 570.98 M |
| Cash And Equivalents | 252.4 M | 2.7 B |
| Cash Per Share | 6.67 X | 5.01 X |
| Total Debt | 1.58 M | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 26.40 X | 2.16 X |
| Book Value Per Share | 3.41 X | 1.93 K |
| Cash Flow From Operations | (100.75 M) | 971.22 M |
| Short Ratio | 2.74 X | 4.00 X |
| Earnings Per Share | (2.84) X | 3.12 X |
| Target Price | 0.55 | |
| Number Of Employees | 65 | 18.84 K |
| Beta | 2.84 | -0.15 |
| Market Capitalization | 20.65 M | 19.03 B |
| Total Asset | 160.25 M | 29.47 B |
| Retained Earnings | (309.21 M) | 9.33 B |
| Working Capital | 125.89 M | 1.48 B |
| Net Asset | 160.25 M |
Note: Disposition of 8510 shares by Worthington Mark of Athira Pharma at 0.5619 subject to Rule 16b-3 [view details]
Athira Pharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Athira . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 43048.15 | |||
| Daily Balance Of Power | 0.2 | |||
| Rate Of Daily Change | 1.02 | |||
| Day Median Price | 0.52 | |||
| Day Typical Price | 0.52 | |||
| Price Action Indicator | 0.02 | |||
| Period Momentum Indicator | 0.01 |
About Athira Pharma Buy or Sell Advice
When is the right time to buy or sell Athira Pharma? Buying financial instruments such as Athira Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Athira Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Electronic Equipment Thematic Idea Now
Electronic Equipment
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Electronic Equipment theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Electronic Equipment Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Athira Pharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Athira Stock refer to our How to Trade Athira Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Athira Pharma. If investors know Athira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Athira Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Athira Pharma is measured differently than its book value, which is the value of Athira that is recorded on the company's balance sheet. Investors also form their own opinion of Athira Pharma's value that differs from its market value or its book value, called intrinsic value, which is Athira Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Athira Pharma's market value can be influenced by many factors that don't directly affect Athira Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Athira Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Athira Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Athira Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.